ASX Share rice
Sun 09 Aug 2020 - 06:53:pm (Sydney)

CPH Share Price

CRESO PHARMA LIMITEDCPHPharmaceuticals, Biotechnology & Life Sciences

CPH Company Information


Creso Pharma Limited




Drug Manufacturers—Specialty & Generic


Tower 3 Sydney NSW Australia 2000


61 2 8067 8606

Co-Founder & Chairman:

Mr. Boaz Wachtel

Co-Founder, Group CEO & Director:

Dr. Miriam Halperin Wernli

Co-Founder & Non-Exec. Director:

Mr. Adam Blumenthal B.Com., M.B.A.

Chief Financial Officer:

Mr. Chris Grundy

Commercial & Marketing Director:

Dr. Gian Trepp

Company Overview:

Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, and the Asia Pacific. The company is involved in hemp growing operations, outsourced CBD extraction, and cannabidiol (CBD) product sales activities, as well as the development and commercialization of its therapeutic products. Its products include anibidiol, a natural complementary feed product for companion animals; and cannaQIX, a nutraceutical product containing organic hemp extract with CBD vitamins and zinc to reduce stress and support mental and nervous functions in humans, as well as topical and skin care products. The company also offers various nutraceutical products, such as cannaQIX®nite to aid sleep; cannaPEAL to introduce various markets to the benefits of hemp seed oil-based products; and cannaDOL to provide relief to athletes in the form of a topical application. In addition, it imports and sells its medicinal cannabis product, cannaQIX50 to patients in Brazil. Creso Pharma Limited has a strategic collaboration agreement with Hempmate AG Switzerland and Burleigh Heads Cannabis Pty Ltd. The company was incorporated in 2015 and is headquartered in Sydney, Australia.

CPH Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


CPH CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


CPH Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Interest Expense:


Total Revenue:


Total Operating Expenses:


Cost Of Revenue:


CPH Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Liabilities:




Total Current Liabilities:


Short-Term Debt:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities Total:


CPH Share Price History

CPH News

05 Dec, 2019
TORONTO , Dec. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced that Creso Pharma Limited ("Creso") (CPH.AX) has repaid in full, all principal and interest owing to the Company in the amount of approximately CAD$3.9 million under the secured bridge loan by PharmaCielo to Creso that was made pursuant to an amendment to Creso's existing loan deed, originally entered into with an arm's length party to Creso on April 26, 2019 (the "Secured Bridge Loan").